Liver Cancer Research
Nivolumab Receives Accelerated Approval from FDA for Advanced Liver CancerPosted: October 20, 2017
The FDA has granted accelerated approval to the immunotherapy drug nivolumab (Opdivo®) for patients with advanced liver cancer who have previously been treated with the targeted therapy sorafenib (Nexavar®).
TCGA study of liver cancer reveals potential targets for therapyPosted: June 15, 2017
Only two drugs are FDA-approved for liver cancer. This study of hepatocellular carcinoma found genetic alterations in tumors—including mutations in tumor-suppressing genes and high expression of immune checkpoint genes—that could be targets for drugs that already exist.
Regorafenib Becomes First FDA-Approved Drug for Liver Cancer in Nearly a DecadePosted: May 24, 2017
FDA approved the kinase inhibitor regorafenib for some patients with hepatocellular carcinoma, the most common form of liver cancer.
Investigators discover new gene that affects clearance of hepatitis C virusPosted: January 7, 2013
Scientists have discovered a new human interferon gene, Interferon Lambda 4 (IFNL4), that affects clearance of the hepatitis C virus. They also identified an inherited genetic variant within IFNL4 that predicts how people respond to treatment for hepatitis C infection.
Combining Angiogenesis-Targeted Treatments for Liver CancerPosted: May 29, 2012
In this trial, patients with unresectable hepatocellular carcinoma who are ineligible for a liver transplant or other local therapies will be given oral sorafenib at the standard approved dose and intravenous TRC105.